Compounds based on the benzoxazine ring system ##STR1## are disclosed for use in enhancing synaptic responses mediated by AMPA receptors. The compounds are effective in the treatment of subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number or strength of excitatory synapses or in the number of AMPA receptors. The compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors, for improving the performance of subjects with memory deficiencies, for treating schizophrenia, and for improving memory encoding.
基于苯并噁嗪环系统的化合物##STR1##被披露用于增强由
AMPA受体介导的突触响应。这些化合物对于治疗因兴奋性突触的数量或强度不足或
AMPA受体数量不足而导致神经或智力功能受损的患者是有效的。这些化合物还可用于治疗无损伤的受试者,以增强依赖利用
AMPA受体的大脑网络的感觉运动和认知任务的表现,以改善记忆缺陷患者的表现,治疗精神分裂症,并改善记忆编码。